Exciting news! Together with our partner, Arrowhead Pharmaceuticals, Sarepta has been named a finalist for the Best Partnership Alliance Award at the Scrip Awards. This Editors’ Choice recognition—finalists are selected by Scrip’s editorial and analyst teams—spotlights the value of biotech companies teaming up to develop new medicines from the earliest stages. It also reflects the strength of our shared commitment to advancing science for patients.
Sarepta Therapeutics
Biotechnology Research
Cambridge, MA 130,251 followers
Dragging Tomorrow Into Today.
About us
Sarepta Therapeutics, headquartered in Cambridge, Massachusetts, is a global biotechnology company on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. For information on our Community Guidelines, please visit sarepta.com/community-guidelines. We want to share a reminder with all job seekers and candidates regarding the persistence of recruiting fraud. Please read a message about recruiting fraud and steps you can take to protect yourself here: https://www.sarepta.com/recruiting-fraud
- Website
-
http://www.sarepta.com
External link for Sarepta Therapeutics
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Cambridge, MA
- Type
- Public Company
Locations
-
Primary
215 First Street
Cambridge, MA 02142, US
-
100 Federal St
Andover, Massachusetts 01810, US
Employees at Sarepta Therapeutics
Updates
-
Brothers Caleb and Dunky do not qualify for any clinical trials and are not currently eligible for many treatments due to their mutation. We’re sharing their story to show the realities of Duchenne when disease-slowing treatments are not an option and to underscore the urgency of our work. Watch this portrait of life with Duchenne. Learn more here: https://bit.ly/3KvHKi9
-
Attending #WMS2025? We will be presenting three oral presentations and five poster presentations at the 30th Annual International Congress of the World Muscle Society, taking place in Vienna, Austria, from Oct 7-11.
-
We look forward to attending the World Muscle Society Annual Congress #WMS2025 as a Diamond Sponsor. Visit us in-person at booth number 7. Learn more at wms2025.com.
-
-
We’re excited to introduce Selim, one of 25 recipients of Sarepta’s 2025–2026 Route 79 Scholarship. As his Duchenne has progressed, Selim has learned to advocate for himself and all that he might achieve. Today, he’s studying Biology and contributing to research that deeply resonates with him. Volume up! Watch to hear Selim’s own words on how he’s thinking about his future. Learn more about the Route 79 Scholarship program and meet other recipients: https://bit.ly/3TmweXI
-
We were thrilled to host Breakfall author Kevin Counterman, DO, alongside patient advocates Buddy Cassidy, who contributed the book’s epilogue, and Alan Chaulet, who is leading its promotion. Breakfall is a fictional story of a family navigating one brother’s life with Duchenne, drawn from Kevin’s own experience. Set in the late 1960s, the novel echoes the era when Dr. Jerry Mendell, Sarepta senior advisor, saw his first Duchenne patient. Thank you all for sharing your stories and sparking a thoughtful conversation around hope, resilience in the Duchenne community and the bonds of family. Pictured (clockwise) are author Dr. Kevin Counterman; Buddy Cassidy; Dr. Jerry Mendell; Alan Chaulet
-
-
Volume up! Meet Charles, one of 25 recipients of Sarepta’s 2025-2026 Route 79 Scholarship and a first-year college student studying Biology. Living with #Duchenne muscular dystrophy, Charles has learned that resilience isn’t about ignoring challenges, it’s about reframing them. He says he now sees Duchenne not as a limitation, but as something that has shaped his determination, work ethic and perspective. Hear his story in his own words. Learn more about the Route 79 Scholarship program and the other 2025-2026 recipients here: https://bit.ly/3TmweXI
-
Katherine and Rachita from our Patient Affairs team had a great time connecting with the community and recognizing World Duchenne Awareness Day over the weekend. Thank you for hosting us, Jett Foundation!
-
-
Wendy Erler, Sarepta’s senior vice president of Patient Affairs, spoke with Dr. Jerry Mendell — gene therapy pioneer and respected Duchenne clinician-researcher — on the occasion of World Duchenne Awareness Day. In this short video, Dr. Mendell reflects on the evolution of gene therapy and Duchenne care over his career, and he shares his hopes for patients today. Watch their conversation. #WDAD2025
-
On World Duchenne Awareness Day – and all this month – we are recognizing recipients of Sarepta’s Route 79 academic scholarship, a program that supports students diagnosed with Duchenne and siblings who are pursuing their post-high school educational goals. Today, we’re featuring Jared, a fourth-year engineering student who’s not one to let expectations hold him back. He sees every challenge as a chance to grow. Watch this video hear his thoughts on resilience and perseverance. (Volume up!) Learn more about the Route 79 Scholarship program and this year’s recipients: https://bit.ly/3TmweXI #WDAD2025